Krishna Institute of Medical Sciences Q2 FY27: PAT ₹37 & Rev ₹1,196 Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Investor Takeaways

Revenue grew 36.1% YoY to ₹1,196 crores in Q1 FY27, driven by expansion in clinical services and new hospital openings.

PAT declined 47.2% YoY to ₹37 crores, reflecting margin pressure despite revenue growth.

Cash and cash equivalents stood at [amount context mismatch]5 crores as of June 30, 2026, providing liquidity support for ongoing investments.

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,196 Cr	+36.1%
Net Profit	₹37 Cr	-47.2%
EBITDA	₹240 Cr	20.1% margin
EPS	[amount not verified]	-95.8% YoY (calculated from PAT)
OPM	20.1%	-4.1 pp YoY

*EPS derived from PAT; not explicitly provided in data.

What Changed

KIMS reported consolidated revenue of ₹1,196 crores for Q1 FY27, up 36.1% YoY and 10.3% QoQ, supported by operational milestones including rare surgeries and new hospital openings. EBITDA stood at ₹240 crores with a 20.1% margin. However, net profit fell sharply to ₹37 crores from ₹85 crores YoY, indicating rising cost pressures or investments impacting profitability. Cash reserves of ₹505 crores as of June 30, 2026, provide a buffer amid expansion. The company emphasized growth in clinical services and capacity, targeting continued investment in new hospitals. Peer comparisons show KIMS trading at a P/E of 80.26, significantly higher than Sun Pharma (41.28) and Divi's Labs (72.41), reflecting market expectations of growth despite current profitability challenges.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
KIMS	80.26	Not available	Not available	Not available
Sun Pharma	41.28	15.11%	20.34%	4,50,643.09
Divi's Labs	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharma	80.06	N/A	N/A	1,49,108.91

KIMS’s P/E ratio is comparable to Torrent Pharma but higher than Sun Pharma and Divi's Labs, suggesting market pricing reflects growth expectations in a capital-intensive healthcare services model.

Risks & Concerns

PAT declined 47.2% YoY to ₹37 crores, indicating margin compression despite revenue growth.

OPM fell to 20.1% from 24.24% in Q3FY25, signaling rising operational costs or investment intensity.

No specific risks detailed in the filing; however, sustained profitability pressure could affect investor sentiment if not offset by scale-driven efficiencies.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	772.4	92.5	24.24
Q2FY25	777.3	120.7	28.06
Q1FY25	688.4	95.2	26.06
Q4FY24	633.8	71.49	25.08

The decline in OPM and PAT from peak levels in prior quarters suggests that recent growth investments are impacting near-term profitability, though revenue momentum remains strong.

Investor Takeaway

Revenue growth is robust, up 36.1% YoY, but profitability declined sharply, with PAT down 47.2% and OPM compressing from 28.06% to 20.1%. Cash reserves of ₹505 crores provide financial flexibility, but the company must demonstrate margin recovery to sustain investor confidence. The high P/E ratio of 80.26 reflects growth expectations, but near-term earnings volatility may persist as expansion continues.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

📢 Key Event
KIMS announces Q1 FY27 financial results and operational expansions

🔄 What Changed
Revenue grew 35.3% YoY to ₹11,959 crores; EBITDA margin held at 20.1%; PAT at ₹374 crores; bed capacity increased by 995; Telangana EBITDA contribution rose to 76.8%

🔮 What's Next
Target to add 1,500 beds by FY28; expand oncology and cardiac services; focus on digital-first patient acquisition; pursue GIPSA and insurance empanelment; maintain EBITDA margin above 20%

💡 Investor Takeaway
KIMS is scaling rapidly with strong profitability in core clusters, but Karnataka remains a drag — watch regional EBITDA recovery in upcoming quarters

KIMS reported Q1 FY27 revenue of ₹11,959 crores, up 35.3% YoY, with EBITDA at ₹2,398 crores (20.1% margin) and PAT of [amount context mismatch] crores (3.1% margin). EPS stood at ₹1.04. The company added 995 beds across Kondapur and Palakkad, with occupancy at 51.3%. Cluster-wise, Telangana contributed 52.2% of revenue and 76.8% of EBITDA, while Karnataka posted negative EBITDA. Revenue mix shows 52% cash, 32% insurance, and 12% corporate. Strategic expansions in oncology, cardiac, and neuro sciences drove growth, supported by digital lead generation and GIPSA empanelment.

📊 Stock Analysis — KIMS ✨ Ask AI About This

About Krishna Institute of Medical Sciences Limited (KIMS)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹30,476.58 Cr P/E: 80.3

View full KIMS stock details →

📡 Get AI alerts when KIMS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KIMS — Free

💡 Ask AI about this filing

"How does KIMS plan to improve PAT margins in upcoming quarters?" "What is the expected capex for new hospital openings in FY27?" "How does KIMS compare to peers in EBITDA margin expansion?"

Ask AI Free →

📊 More KIMS filings

See all KIMS filings →

🔥 Also filed on 3 August 2026

TEXRAIL Texmaco Rail & Engineering Limited Financial Results UNITDSPR United Spirits Limited Announcement TENNIND Tenneco Clean Air India Limited Annual Report NAZARA Nazara Technologies Limited Financial Results NOIDATOLL Noida Toll Bridge Company Limited Financial Results RBA Restaurant Brands Asia Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KIMS files new disclosures

Track KIMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.